SCHEDULE: RA Capital Discloses 6.5% Stake in Xencor
Beneficial Ownership Report
RA Capital Management and its affiliates have reported a 6.5% beneficial ownership stake in Xencor, Inc., totaling 4,736,739 shares of common stock.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their ownership in Xencor, Inc.
- The Reporting Persons collectively beneficially own 4,736,739 shares of Xencor, Inc. common stock.
- This ownership represents 6.5% of Xencor, Inc.'s outstanding common stock.
- The percentage is based on 73,338,642 shares outstanding as of February 17, 2026, as reported in Xencor's Annual Report on Form 10-K filed on February 25, 2026.
- The Reporting Persons share both voting and dispositive power over all 4,736,739 shares.
- The securities were not acquired or held for the purpose of changing or influencing the control of Xencor, Inc.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investment firm like RA Capital Management taking a 6.5% stake can be interpreted as a vote of confidence in Xencor's long-term prospects, although the filing itself is purely informational.
Industry Context
StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, often signaling investor confidence or strategic positioning within the biotechnology sector. RA Capital Management is a prominent healthcare-focused investment firm, and their disclosure of a substantial stake in Xencor, a clinical-stage biopharmaceutical company, indicates a notable investment in the sector.
Stakeholder Impact
- Shareholders may view the disclosure of a significant institutional stake as a positive indicator of investor confidence in Xencor, Inc.
Key Dates
| Date | Description |
|---|---|
| 2026-02-17 | Date of shares outstanding calculation (73,338,642 shares) as reported in Xencor's 10-K. |
| 2026-02-25 | Date Xencor, Inc. filed its Annual Report on Form 10-K, which reported the shares outstanding. |
| 2026-03-23 | Date of event which requires the filing of this Schedule 13G. |
| 2026-03-30 | Date of signing for the Schedule 13G and the Joint Filing Agreement. |
Keywords
Xencor Inc, XNCR, RA Capital Management, Peter Kolchinsky, Rajeev Shah, Beneficial Ownership, Schedule 13G, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.